The use of Poly ADP-Ribose Polymerase (PARP) inhibitors is being expanded as therapeutic alternative in multiple types of cancer beyond BRCA1/2 mutant breast and ovarian cancer. This evidence concerns the gene BRCA1 and ovarian cancer.